RVMD Stock Holds Steady After FDA Approval of $39,800/Month Pancreatic Cancer Pill
· profitconfidential.com
The U.S. Food and Drug Administration (FDA) has granted approval for Rasonque, a once-daily oral medication, targeting adults diagnosed with metastatic
RVMD Stock Holds Steady After FDA Approval of $39,800/Month Pancreatic Cancer Pill – Is the Sky-High Price Dimming Investor Excitement?
The U.S. Food and Dru...